Diabetes mellitus due to underlying condition with diabetic chronic kidney disease
Methodology & AI Transparency ⓘ
Diabetes mellitus due to underlying condition with diabetic chronic kidney disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Diabetes mellitus due to underlying condition with diabetic chronic kidney disease (E08.22; Type 1 & Type 2 Diabetes) utilize continuous glucose monitoring in Diabetes mellitus due to underlying condition with diabetic chronic kidney disease (E08.22: (CGM) glycemic variability) and objective Hemoglobin A1c (HbA1c) [Diabetes mellitus due to underlying condition with diabetic chronic kidney disease E08.22] targets (4.8% – 5.6% (< 6.5% clinical target) (E08.22)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Federal ICD-10-CM code E08.22 categorizes Diabetes mellitus due to underlying condition with diabetic chronic kidney disease under Type 1 & Type 2 Diabetes.
- 3 Typical cash cost range: Primary evaluation for Diabetes mellitus due to underlying condition with diabetic chronic kidney disease incorporates continuous glucose monitoring in Diabetes mellitus due to underlying condition with diabetic chronic kidney disease (E08.22: (CGM) glycemic variability) and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Diabetes mellitus due to underlying condition with diabetic chronic kidney disease monitoring tracks Hemoglobin A1c (HbA1c) [Diabetes mellitus due to underlying condition with diabetic chronic kidney disease E08.22] toward 4.8% – 5.6% (< 6.5% clinical target) (E08.22).
Ask our AI Specialists anything about Diabetes mellitus due to underlying condition with diabetic chronic kidney disease
What Is Diabetes mellitus due to underlying condition with diabetic chronic kidney disease?
Physicians managing Diabetes mellitus due to underlying condition with diabetic chronic kidney disease (E08.22; Type 1 & Type 2 Diabetes) utilize continuous glucose monitoring in Diabetes mellitus due to underlying condition with diabetic chronic kidney disease (E08.22: (CGM) glycemic variability) and objective Hemoglobin A1c (HbA1c) [Diabetes mellitus due to underlying condition with diabetic chronic kidney disease E08.22] targets (4.8% – 5.6% (< 6.5% clinical target) (E08.22)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Diabetes mellitus due to underlying condition with diabetic chronic kidney disease (E08.22) center on unrestrained hepatic gluconeogenesis [Diabetes mellitus due to underlying condition with diabetic chronic kidney disease E08.22]. targeted diabetes & glucose interventions aim to normalize Hemoglobin A1c (HbA1c) [Diabetes mellitus due to underlying condition with diabetic chronic kidney disease E08.22].
Common Symptoms & Clinical Signs
- • Presentation of Diabetes mellitus due to underlying condition with diabetic chronic kidney disease (E08.22): blurred vision fluctuations in Diabetes mellitus due to underlying condition with diabetic chronic kidney disease (E08.22: or slower healing)
- • Secondary Diabetes mellitus due to underlying condition with diabetic chronic kidney disease clinical sign: elevated fasting blood in Diabetes mellitus due to underlying condition with diabetic chronic kidney disease (E08.22: glucose or post-meal)
- • Symptom flares in Diabetes mellitus due to underlying condition with diabetic chronic kidney disease correlating with Hemoglobin A1c (HbA1c) [Diabetes mellitus due to underlying condition with diabetic chronic kidney disease E08.22] deviation outside 4.8% – 5.6% (< 6.5% clinical target) (E08.22)
- • Functional diabetes & glucose impact requiring continuous glucose monitoring in Diabetes mellitus due to underlying condition with diabetic chronic kidney disease (E08.22: (CGM) glycemic variability) evaluation (E08.22)
Diabetes mellitus due to underlying condition with diabetic chronic kidney disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E08.22 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NLM Clinical Tables |
| Diagnostic / Lab Marker: Hemoglobin A1c (HbA1c) [Diabetes mellitus due to underlying condition with diabetic chronic kidney disease E08.22] | 4.8% – 5.6% (< 6.5% clinical target) (E08.22) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Diabetes mellitus due to underlying condition with diabetic chronic kidney disease E08.22] | 75 – 95 mg/dL (E08.22) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Insulin [Diabetes mellitus due to underlying condition with diabetic chronic kidney disease E08.22] | 3.0 – 7.0 uIU/mL (E08.22) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Diabetes mellitus due to underlying condition with diabetic chronic kidney disease
Treatment selection for Diabetes mellitus due to underlying condition with diabetic chronic kidney disease depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Diabetes mellitus due to underlying condition with diabetic chronic kidney disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of empagliflozin as add-on to metformin for type 2: What a 4,256-Participant Study Found EMPA as add-on to MET was well tolerated and provided additional benefits beyond glucose lowering, such as weight loss and blood pressure reduction. European journal of clinical pharmacology • 2016-06-15 • Meta-Analysis | N = 4,256 | 99/100 | PMID 26832915 ↗ |
| New Insights on Is metformin still the most efficacious first-line oral hypoglycaemic drug in: What a 33,830-Participant Study Found This meta-analysis showed that repaglinide and metformin would be the most efficacious oral drugs for first-line single-drug treatment of T2DM. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2019-01-15 • Meta-Analysis | N = 33,830 | 99/100 | PMID 30230172 ↗ |
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Urinary tract infections in patients with diabetes treated with: What a 3,152-Participant Study Found Treatment of type 2 diabetes with once-daily dapagliflozin 5 or 10mg is accompanied by a slightly increased risk of urinary tract infection. Journal of diabetes and its complications • 2013-01-15 • Meta-Analysis | N = 3,152 | 99/100 | PMID 23849632 ↗ |
| New Insights on Effect of metformin on microvascular outcomes in patients with type 2: What a 18,181-Participant Study Found There is no evidence of clinically significant beneficial effect of metformin therapy as compared to other glucose-lowering medications or placebo on the examined microvascular complications. Diabetes research and clinical practice • 2022-04-15 • Meta-Analysis | N = 18,181 | 99/100 | PMID 35247521 ↗ |
Diabetes mellitus due to underlying condition with diabetic chronic kidney disease Patient Community & “People Like Me” Threads
Filter Diabetes mellitus due to underlying condition with diabetic chronic kidney disease community threads and patient logs by age, biological sex, dosage, and treatment duration.